首页|动态监测ProGRP、NSE、CYFRA21-1、SCCAg水平在肺癌化疗中的应用价值

动态监测ProGRP、NSE、CYFRA21-1、SCCAg水平在肺癌化疗中的应用价值

扫码查看
目的 探讨连续监测血清胃泌素释放肽前体(ProGRP)、神经元特异性烯醇化酶(NSE)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、鳞状细胞癌抗原(SCC-Ag)在不同化疗周期中的表达变化对肺癌病理分型及化疗疗效评价的临床应用价值。方法 选选取125例确诊肺癌患者,其中包括小细胞肺癌(SCLC)16例、肺鳞癌(LUSC)32例和肺腺癌(LUAD)77例,连续检测化疗不同轮次周期患者的血清肿瘤标志物水平,并分析其与肺癌病理分型、疗效评价及预后的相关性。同期选取500名健康体检者作为对照组,建立正常人群肿瘤标志物基线数据。结果 SCLC 组 ProGRP、NSE 水平显著高于 LUSC 和 LUAD 组(P<0。05);LUSC 组 CYFRA21-1、SCC-Ag 水平显著高于其他组(P<0。05);LUAD组CYFRA21-1水平高于SCLC组(P<0。05)。SCLC疗效有效组化疗后Pro-GRP、NSE水平显著下降(P<0。05),且与疗效评价呈正相关(P<0。05);LUSC组CYFRA21-1、SCC-Ag化疗后水平明显低于化疗中和化疗前,且与疗效评价呈正相关(P<0。05)。化疗疗效为PD的患者其肿瘤标志物水平在化疗前、中、后差异无统计学意义(P>0。05)。LUAD患者化疗前后CYFRA21-1水平差异有统计学意义(P<0。05),且CYFRA21-1、NSE与疗效评价呈正相关(P<0。05)。结论 连续动态监测ProGRP、NSE、CYFRA21-1、SCC-Ag水平对肺癌病理分型及化疗疗效评估具有一定价值。
The application value of dynamic monitoring of ProGRP,NSE,CYFRA21-1,and SCCAg levels in lung cancer chemotherapy
Objective To explore the clinical application value of continuous monitoring of the expression changes of serum ProGRP,NSE,CYFRA21-1,and SCC Ag in different chemotherapy cycles for pathological classification of lung cancer and evaluation of chemotherapy efficacy.Methods 125 confirmed lung cancer patients were selected,including 16 cases of small cell lung cancer(SCLC),32 cases of lung squamous cell carcinoma(LUSC),and 77 ca-ses of lung adenocarcinoma(LUAD).Serum tumor marker levels were continuously measured in patients with dif-ferent cycles of chemotherapy,and their correlation with lung cancer pathological classification,treatment efficacy e-valuation,and prognosis was analyzed.500 healthy examinees were selected as the control group during the same period to establish baseline data for tumor markers in the normal population.Result The levels of ProGRP and NSE in the SCLC group were significantly higher than those in the LUSC and LUAD groups(P<0.05);The levels of CYFRA21-1 and SCC Ag in the LUSC group were significantly higher than those in the other groups(P<0.05);The CYFRA21-1 level in the LUAD group was higher than that in the SCLC group(P<0.05).The levels of Pro-GRP and NSE in the SCLC effective group significantly decreased after chemotherapy(P<0.05),and were posi-tively correlated with efficacy evaluation(P<0.05);The levels of CYFRA21-1 and SCC Ag in the LUSC group were significantly lower after chemotherapy than before and during chemotherapy,and were positively correlated with efficacy evaluation(P<0.05).There was no statistically significant difference in tumor marker levels among patients with PD who received chemotherapy before,during,and after chemotherapy(P>0.05).There was a sta-tistically significant difference in the levels of CYFRA21-1 and SCC Ag in LUAD patients before and after chemo-therapy(P<0.05),and CYFRA21-1 and NSE were positively correlated with efficacy evaluation(P<0.05).Conclusion Continuous dynamic monitoring of ProGRP,NSE,CYFRA21-1,and SCC Ag levels has certain value in the patho-logical classification and chemotherapy efficacy evaluation of lung cancer.

Lung cancerTumor markersChemotherapyPathological classificationEfficacy evaluation

胡丽梅、袁泉、梁乃旭、叶兆军、郑智弦

展开 >

梧州市红十字会医院检验科,广西梧州 543000

肺癌 肿瘤标志物 化疗 病理分型 疗效评价

2025

贵州医药
贵州省医药卫生学会办公室

贵州医药

影响因子:0.493
ISSN:1000-744X
年,卷(期):2025.49(1)